Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines

UNSPECIFIED (2012) Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines. PLoS ONE, 7 (7).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (447kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Breast cancer patients have different responses to chemotherapeutic treatments. Genes associated with drug response can provide insight to understand the mechanisms of drug resistance, identify promising therapeutic opportunities, and facilitate personalized treatment. Estrogen receptor (ER) positive and ER negative breast cancer have distinct clinical behavior and molecular properties. However, to date, few studies have rigorously assessed drug response genes in them. In this study, our goal was to systematically identify genes associated with multidrug response in ER positive and ER negative breast cancer cell lines. We tested 27 human breast cell lines for response to seven chemotherapeutic agents (cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil, gemcitabine, and paclitaxel). We integrated publicly available gene expression profiles of these cell lines with their in vitro drug response patterns, then applied meta-analysis to identify genes related to multidrug response in ER positive and ER negative cells separately. One hundred eighty-eight genes were identified as related to multidrug response in ER positive and 32 genes in ER negative breast cell lines. Of these, only three genes (DBI, TOP2A, and PMVK) were common to both cell types. TOP2A was positively associated with drug response, and DBI was negatively associated with drug response. Interestingly, PMVK was positively associated with drug response in ER positive cells and negatively in ER negative cells. Functional analysis showed that while cell cycle affects drug response in both ER positive and negative cells, most biological processes that are involved in drug response are distinct. A number of signaling pathways that are uniquely enriched in ER positive cells have complex cross talk with ER signaling, while in ER negative cells, enriched pathways are related to metabolic functions. Taken together, our analysis indicates that distinct mechanisms are involved in multidrug response in ER positive and ER negative breast cells. © 2012 Shen et al.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Contributors:
ContributionContributors NameEmailPitt UsernameORCID
EditorKatz, EladUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Date: 16 July 2012
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 7
Number: 7
DOI or Unique Handle: 10.1371/journal.pone.0040900
Schools and Programs: Graduate School of Public Health > Biostatistics
Refereed: Yes
Other ID: NLM PMC3397945
PubMed Central ID: PMC3397945
PubMed ID: 22815861
Date Deposited: 05 Oct 2012 19:08
Last Modified: 05 Jan 2019 16:00
URI: http://d-scholarship.pitt.edu/id/eprint/15588

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item